The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers.
Antonio Calles
No relevant relationships to disclose
Xiaoyun Liao
No relevant relationships to disclose
Lynette M. Sholl
No relevant relationships to disclose
Mohit Butaney
No relevant relationships to disclose
Scott J. Rodig
No relevant relationships to disclose
Gordon James Freeman
Consultant or Advisory Role - Costim Pharmaceuticals (B)
Stock Ownership - Costim Pharmaceuticals (B)
Christine A. Lydon
No relevant relationships to disclose
Geoffrey R. Oxnard
Consultant or Advisory Role - AstraZeneca; Genentech
David Michael Jackman
Consultant or Advisory Role - Foundation Medicine; Genentech
Honoraria - Chugai Pharma
Pasi A. Janne
Consultant or Advisory Role - AstraZeneca